Antiproliferative effects of D-allose associated with reduced cell division frequency in glioblastoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 11 2023
09 11 2023
Historique:
received:
07
10
2022
accepted:
05
11
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Recent studies have shown that D-allose, a rare sugar, elicits antitumor effects on different types of solid cancers, such as hepatocellular carcinoma, non-small-cell lung cancer, and squamous cell carcinoma of the head and neck. In this study, we examined the effects of D-allose on the proliferation of human glioblastoma (GBM) cell lines (i.e., U251MG and U87MG) in vitro and in vivo and the underlying mechanisms. D-allose treatment inhibited the proliferation of U251MG and U87MG cells in a dose-dependent manner (3-50 mM). However, D-allose treatment did not affect cell cycles or apoptosis in these cells but significantly decreased the cell division frequency in both GBM cell lines. In a subcutaneous U87MG cell xenograft model, intraperitoneal injection of D-allose (100 mg/kg/day) significantly reduced the tumor volume in 28 days. These data indicate that D-allose-induced reduction in cell proliferation is associated with a subsequent decrease in the number of cell divisions, independent of cell-cycle arrest and apoptosis. Thus, D-allose could be an attractive additive to therapeutic strategies for GBM.
Identifiants
pubmed: 37945736
doi: 10.1038/s41598-023-46796-4
pii: 10.1038/s41598-023-46796-4
pmc: PMC10636159
doi:
Substances chimiques
allose
6038-51-3
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19515Informations de copyright
© 2023. The Author(s).
Références
Cancer Lett. 2011 Jul 1;306(1):60-6
pubmed: 21439723
Head Neck. 2009 Aug;31(8):1049-55
pubmed: 19340872
Int J Oncol. 2014 Nov;45(5):2044-50
pubmed: 25109398
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Tohoku J Exp Med. 2016;238(2):131-41
pubmed: 26829886
Oncol Rep. 2018 Mar;39(3):1292-1298
pubmed: 29328484
J Transl Med. 2018 May 29;16(1):142
pubmed: 29843811
J Neurosurg. 2017 Oct;127(4):819-828
pubmed: 28059652
J Stroke Cerebrovasc Dis. 2016 Sep;25(9):2184-8
pubmed: 27342700
Drug Des Devel Ther. 2015 Jan 17;9:525-35
pubmed: 25632221
J Biosci Bioeng. 2008 Sep;106(3):248-52
pubmed: 18930000
Oncol Lett. 2018 Mar;15(3):3422-3428
pubmed: 29456721
PLoS Biol. 2019 Mar 13;17(3):e3000178
pubmed: 30865623
Neurol Med Chir (Tokyo). 2013;53(6):365-74
pubmed: 23803614
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Anticancer Res. 2005 Jul-Aug;25(4):2639-44
pubmed: 16080505
Adv Exp Med Biol. 2019;1164:199-206
pubmed: 31576550
Ann Otol Rhinol Laryngol. 2010 Aug;119(8):567-71
pubmed: 20860283
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Int J Oncol. 2008 Feb;32(2):377-85
pubmed: 18202760